[Analyst Report] Forward path clear — ST PHARM

Science & Technology
- Business Overview
- CDMO
- CRO
  - AnaPath Research & Service
- R&D
  - Virtual R&D
  - Global R&D
About
Public
- PR (Public Relations)
  - News room
- IR (Investor Relations)
  - Stock Information
  - IR Library
Careers
ESG

Linkedin

Public

IR Materials

PR (Public Relations)
- News room
IR (Investor Relations)
- Stock Information
- IR Library

IR Materials

Oct 20, 2022

[Analyst Report] Forward path clear

- BUY maintained; 6M TP bumped down 17.2% to W120,000.

- 3Q22 OP to meet expectation, even with sales deferred from 2Q22.

「반출」ST_Pharm_Daishin_Securities_20221020101439.pdf